Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
Φόρτωση...
Ημερομηνία
Συγγραφείς
Pavlidis, N.
Aamdal, S.
Awada, A.
Calvert, H.
Fumoleau, P.
Sorio, R.
Punt, C.
Verweij, J.
van Oosterom, A.
Morant, R.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Cancer Chemother Pharmacol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
PURPOSE: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 microg/m2. A total of 140 patients were entered and a total of 285 courses were administered. RESULTS: In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets. Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. CONCLUSIONS: At this dose and schedule carzelesin did not yield activity in the types of tumors studied.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use, Benzofurans/administration & dosage/adverse effects/*therapeutic use, Breast Neoplasms/drug therapy, Colorectal Neoplasms/drug therapy, Female, Head and Neck Neoplasms/drug therapy, Humans, Indoles/administration & dosage/adverse effects/*therapeutic use, Infusions, Intravenous, Lymphoma, Non-Hodgkin/drug therapy, Male, Melanoma/drug therapy, Middle Aged, Neoplasm Staging, Neoplasms/*drug therapy/pathology, Ovarian Neoplasms/drug therapy, Prodrugs/adverse effects/*therapeutic use, Stomach Neoplasms/drug therapy
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/10972487
http://www.springerlink.com/content/8um0pnej4jhdwdtn/fulltext.pdf
http://www.springerlink.com/content/8um0pnej4jhdwdtn/fulltext.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής